- Home
- SCNX vs LIXT Comparison
SCNX vs LIXT Comparison
Compare SCNX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- LIXT
- Stock Information
- Founded
- SCNX 2010
- LIXT 2005
- Country
- SCNX United States
- LIXT United States
- Employees
- SCNX N/A
- LIXT N/A
- Industry
- SCNX Other Pharmaceuticals
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- LIXT Health Care
- Exchange
- SCNX Nasdaq
- LIXT Nasdaq
- Market Cap
- SCNX 21.2M
- LIXT 24.4M
- IPO Year
- SCNX 2020
- LIXT N/A
- Fundamental
- Price
- SCNX $0.69
- LIXT $4.58
- Analyst Decision
- SCNX
- LIXT
- Analyst Count
- SCNX 0
- LIXT 0
- Target Price
- SCNX N/A
- LIXT N/A
- AVG Volume (30 Days)
- SCNX 186.1K
- LIXT 139.7K
- Earning Date
- SCNX 11-05-2025
- LIXT 11-11-2025
- Dividend Yield
- SCNX N/A
- LIXT N/A
- EPS Growth
- SCNX N/A
- LIXT N/A
- EPS
- SCNX N/A
- LIXT N/A
- Revenue
- SCNX $128,202.00
- LIXT N/A
- Revenue This Year
- SCNX N/A
- LIXT N/A
- Revenue Next Year
- SCNX N/A
- LIXT N/A
- P/E Ratio
- SCNX N/A
- LIXT N/A
- Revenue Growth
- SCNX N/A
- LIXT N/A
- 52 Week Low
- SCNX $0.67
- LIXT $0.64
- 52 Week High
- SCNX $9.55
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- SCNX 28.59
- LIXT 47.37
- Support Level
- SCNX $0.67
- LIXT $4.04
- Resistance Level
- SCNX $0.89
- LIXT $4.97
- Average True Range (ATR)
- SCNX 0.08
- LIXT 0.47
- MACD
- SCNX 0.01
- LIXT -0.12
- Stochastic Oscillator
- SCNX 4.14
- LIXT 41.36
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.